TOLREMO therapeutics AG is a pre-clinical stage biotechnology company pursuing a novel approach to preventing cancer drug resistance and treating aggressive tumors. Founded in 2017 out of ETH Zurich, the company uses a proprietary technology platform to develop small molecule inhibitors that target a tumor’s faulty software; i.e. gene regulatory programs that are aberrantly expressed in cancer cells. Thanks to this innovative therapeutic concept TOLREMO’s drugs have the potential to improve the long-term efficacy of existing cancer therapies and to treat aggressive cancers which cannot be managed with currently available therapies.